Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.12.2023 | Case report

Dabigatran-etexilate

Various toxicities: 21 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Dai JW, et al. Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials. Medicina (Kaunas, Lithuania) 59: 1-13, No. 5, et al. May 2023. Available from: URL: http://doi.org/10.3390/medicina59050881 Dai JW, et al. Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials. Medicina (Kaunas, Lithuania) 59: 1-13, No. 5, et al. May 2023. Available from: URL: http://​doi.​org/​10.​3390/​medicina59050881​
Metadaten
Titel
Dabigatran-etexilate
Various toxicities: 21 case reports
Publikationsdatum
01.12.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51832-9

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Heparin

Case report

Methotrexate

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Etonogestrel

Case report

Eravacycline